Endothelial cell protection and complement inhibition in xenotransplantation: A novel in vitro model using whole blood

Xenotransplantation

Volumn 12, Issue 6, 2005, Pages 434-443

  Banz, Yara ^a   Cung, Trinh ^a   Korchagina, Elena Y ^b   Bovin, Nicolai V ^b   Haeberli, André ^a   Rieben, Robert ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Complement; Dextran sulfate; Endothelium; In vitro model; Microcarrier beads; Whole blood

Indexed keywords

BLOOD CLOTTING FACTOR; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4C; COMPLEMENT MEMBRANE ATTACK COMPLEX; DEXTRAN SULFATE; FIBRINOPEPTIDE A; FLUORESCEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHATE BUFFERED SALINE; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE GRAFT REJECTION; ANIMAL CELL; AORTA; ARTICLE; BLOOD; BLOOD CLOTTING; CELL ACTIVATION; CELL DAMAGE; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; MICROCARRIER CULTURE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SWINE; VASCULAR ENDOTHELIUM; XENOTRANSPLANTATION;

ANIMALS; CELLS, CULTURED; COMPLEMENT HEMOLYTIC ACTIVITY ASSAY; COMPLEMENT SYSTEM PROTEINS; CYTOPROTECTION; ENDOTHELIAL CELLS; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS; MICROSCOPY, FLUORESCENCE; MODELS, IMMUNOLOGICAL; SWINE; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 27144554039     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2005.00239.x     Document Type: Article

References (39)

1. PRUITT SK, KIRK AD, BOLLINGER RR et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363.
2. LEVENTHAL JR, DALMASSO AP, CROMWELL JW et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
3. PALMETSHOFER A, GALILI U, DALMASSO AP et al. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: Type i activation. Transplantation 1998; 65: 844.
4. PALMETSHOFER A, GALILI U, DALMASSO AP et al. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: Type ii activation. Transplantation 1998; 65: 971.
5. PLATT JL, VERCELLOTTI GM, LINDMAN BJ et al. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171: 1363.
6. NAGAYASU T, SAADI S, HOLZKNECHT RA et al. Expression of tissue factor mRNA in cardiac xenografts: clues to the pathogenesis of acute vascular rejection. Transplantation 2000; 69: 475.
7. ROBSON SC, YOUNG VK, COOK NS et al. Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection. Transplantation 1996; 61: 862.
8. SOLVIK UO, HARALDSEN G, FIANE AE et al. Human serum-induced expression of E-selectin on porcine aortic endothelial cells in vitro is totally complement mediated. Transplantation 2001; 72: 1967.
9. HAUZENBERGER E, HAUZENBERGER D, HULTENBY K, HOLGERSSON J. Porcine endothelium supports transendothelial migration of human leukocyte subpopulations: Anti-porcine vascular cell adhesion molecule antibodies as species-specific blockers of transendothelial monocyte and natural killer cell migration. Transplantation 2000; 69: 1837.
10. KOPP CW, SIEGEL JB, HANCOCK WW et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63: 749.
11. SIEGEL JB, GREY ST, LESNIKOSKI BA et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64: 888.
12. KOPP CW, GREY ST, SIEGEL JB et al. Expression of human thrombomodulin cofactor activity in porcine endothelial cells. Transplantation 1998; 66: 244.
13. CHEN D, RIESBECK K, MCVEY JH et al. Regulated inhibition of coagulation by porcine endothelial cells expressing P-selectin-tagged hirudin and tissue factor pathway inhibitor fusion proteins. Transplantation 1999; 68: 832.
14. LAUMONIER T, MOHACSI PJ, MATOZAN KM et al. Endothelial cell protection by dextran sulfate: a novel strategy to prevent acute vascular rejection in xenotransplantation. Am J Transplant 2004; 4: 181.
15. COZZI E, WHITE DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964.
16. BIEDERMANN B, ROSENMUND A, MULLER M et al. Human endothelial cells suppress prothrombin activation in non-anticoagulated whole blood in vitro. J Lab Clin Med 1994; 124: 339.
17. MERI S, PANGBURN MK. Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun 1994; 198: 52.
18. WUILLEMIN WA, TE VELTHUIS H, LUBBERS YT et al. Potentiation of c1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 1997; 159: 1953.
19. LAUMONIER T, WALPEN A, MAURUS C et al. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement - and NK cell-mediated cytotoxicity against porcine cells. Transplantation 2003; 76: 838.
20. ZEERLEDER S, MAURON T, LAMMLE B, WUILLEMIN WA. Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. Thromb Res 2002; 105: 441.
21. BURGESS WH, MEHLMAN T, FRIESEL R et al. Multiple forms of endothelial cell growth factor. Rapid isolation and biological and chemical characterization. J Biol Chem 1985; 260: 11389.
22. DAHA MR, VAN Es LA. Enhanced alternative complement pathway-dependent degradation of soluble immunoglobulin aggregates by macrophages. Immunology 1981; 43: 513.
23. MCCURRY KR, KOOYMAN DL, ALVARADO CG et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995; 1: 423.
24. CANDINAS D, LESNIKOSKI BA, HANCOCK WW et al. Inhibition of platelet integrin GPIIbIIIa prolongs survival of discordant cardiac xenografts. Transplantation 1996; 62: 1.
25. WANG H, ROLLINS SA, GAO Z et al. Complement inhibition with an anti-c5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model. Transplantation 1999; 68: 1643.
26. ROBSON SC, KACZMAREK E, SIEGEL JB et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185: 153.
27. LAUMONIER T, WALPEN AJ, MATOZAN KM et al. Multimeric tyrosine sulfate acts as an endothelial cell protectant and prevents complement activation in xenotransplantation models. Xenotransplantation 2004; 11: 262.
28. SCHRIMPF G, FRIEDL P. Growth of human vascular endothelial cells on various types of microcarriers. Cytotechnology 1993; 13: 203.
29. BUSCH C, CANCILLA PA, DEBAULT LE et al. Use of endothelium cultured on microcarriers as a model for the microcirculation. Lab Invest 1982; 47: 498.
30. BENNET W, SUNDBERG B, ELGUE G et al. A new in vitro model for the study of pig-to-human vascular hyperacute rejection. Xenotransplantation 2001; 8: 176.
31. SHIMADA K, OZAWA T. Evidence that cell surface heparan sulfate is involved in the high affinity thrombin binding to cultured porcine aortic endothelial cells. J Clin Invest 1985; 75: 1308.
32. ESMON CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348.
33. LENICH C, PANNELL R, GUREWICH V. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb Haemost 1995; 74: 698.
34. BOURIN MC, LINDAHL U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289 (Pt 2): 313.
35. MAURON T, LAMMLE B, WUILLEMIN WA. Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins. Thromb Haemost 1998; 80: 82.
36. KNISEL W, DI NICUOLO A, PFOHL M et al. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems. J Intern Med 1993; 234: 479.
37. KOJIMA S, HARADA-SHIBA M, TOYOTA Y et al. Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int J Artif Organs 1992; 15: 185.
38. KOJIMA S, HARADA-SHIBA M, YAMAMOTO A. Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column. Ther Apher 1997; 1: 309.
39. FIORANTE P, BANZ Y, MOHACSI PJ et al. Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models. Xenotransplantation 2001; 8: 24.